Business
Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update
Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial and operational results for the first quarter of 2026.
About this update from Theravance Biopharma, Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"YUPELRI® Collaboration Revenue increased 15% year-over-year1, from $15.4 million to $17.7 million, driven by continued Net Sales growth and improved operating leverage","length":167,"tagName":"p"}]},{"val":[{"type":"text","content":"All Hatch-Waxman litigation relating to YUPELRI® has been resolved following settlement with Mankind Pharma in March","length":116,"tagName":"p"}]},{"val":[{"type":"text","content":"Organizational restructuring and cost reduction initiatives on track; delivered ~20% reduction in Operating Expenses year-over-year (excluding restructuring items)","length":163,"tagName":"p"}]},{"val":[{"type":"text","content":"Q1 2026 TRELEGY net sales, reported by GSK, of $873 million, up 2% year-over-year; high confidence in achieving the $100 million 2026 milestone payment2","length":152,"tagName":"p"}]},{"val":[{"type":"text","content":"Strategic Review Committee actively evaluating a range of opportunities to maximize shareholder value","length":101,"tagName":"p"}]},{"val":[{"type":"text","content":"Quarter-end cash balance of $395 million and no debt","length":52,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":751,"olType":false},{"type":"text","content":"DUBLIN, May 7, 2026 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial and operational results for the first quarter of 2026.","length":219,"tagName":"p"},{"type":"image","alt":"Theravance Biopharma Logo (PRNewsfoto/Theravance Biopharma, Inc.)","displaySize":"","headline":null,"caption":"Theravance Biopharma Logo (PRNewsfoto/Theravance Biopharma, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":94,"url":"https://media.zenfs.com/en/prnewswire.com/4d2df003249986704ef2ebec0198a9bd"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/OeaSPvh7K1EXJHa8XMETXw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE2Ng--/https://media.zenfs.com/en/prnewswire.com/4d2df003249986704ef2ebec0198a9bd","width":400,"height":94},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/Lg29IspmSrcP_42k7Zfpzg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTE1MA--/https://media.zenfs.com/en/prnewswire.com/4d2df003249986704ef2ebec0198a9bd","width":400,"height":94}},"href":"https://mma.prnewswire.com/media/557290/Theravance_Biopharma_Logo...